Continued from page 1

Simpson estimated that it would take about $1 million and two to three years to bring the Ebola product to where Corgenix’s Lassa fever test is now.

ReLASV last year received CE Mark approval, which allows for the product’s sale and diagnostic use in the European Union and other international markets.


Information from: Daily Camera,